Similar articles

• Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

  Gaston C, Kolesar J. Gaston C, et al. Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33. Clin Adv Hematol Oncol. 2008. PMID: 19194367
• Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.

  Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU. Bonanni B, et al. J Clin Oncol. 2006 Aug 1;24(22):3708-9; author reply 3709. doi: 10.1200/JCO.2006.06.8072. J Clin Oncol. 2006. PMID: 16877740 No abstract available.
• CYP2D6 genotype and tamoxifen response.

  Rae JM, Goetz MP, Hayes DF, Ingle JN, Li L, Storniolo AM, Stearns V, Flockhart DA. Rae JM, et al. Breast Cancer Res. 2005 Jul 29;7(5):E6. doi: 10.1186/bcr1297. Breast Cancer Res. 2005. PMID: 16168100 Free PMC article. No abstract available.
• Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

  Brauch H, Jordan VC. Brauch H, et al. Eur J Cancer. 2009 Sep;45(13):2274-83. doi: 10.1016/j.ejca.2009.05.032. Epub 2009 Jul 9. Eur J Cancer. 2009. PMID: 19592233 Review.
• Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

  Briest S, Stearns V. Briest S, et al. Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Clin Adv Hematol Oncol. 2009. PMID: 19398943 Review.